Literature DB >> 15015570

Activated Akt expression has significant correlation with EGFR and TGF-alpha expressions in stage I NSCLC.

Toru Mukohara1, Shinzoh Kudoh, Kuniomi Matsuura, Setsuko Yamauchi, Tatsuo Kimura, Naruo Yoshimura, Hiroshi Kanazawa, Kazuto Hirata, Kiyotoshi Inoue, Hideki Wanibuchi, Shoji Fukushima, Junichi Yoshikawa.   

Abstract

BACKGROUND: In vitro studies have indicated that epidermal growth factor receptor (EGFR) may intensify signaling output by the receptor's overexpression, heterodimerization with HER-2, or autocrine expression of ligands. The purpose of the present study was to evaluate the correlation between EGFR and its related proteins and to explore the prognostic value of the proteins.
MATERIALS AND METHODS: Immunohistochemical staining of transforming growth factor alpha (TGF-alpha), EGFR, HER-2, and phosphorylated (p-)Akt was performed in specimens surgically excised from 91 consecutive patients with p-stage I non-small cell lung cancer (NSCLC). Expression or coexpression of TGF-alpha and the receptors were related to expression of p-Akt. The prognostic impact of these peptides was also tested.
RESULTS: TGF-alpha, EGFR and HER-2 overexpressions were detected in 32%, 79% and 13% of tumors, respectively. Coexpressions of TGF-alpha & EGFR and EGFR & HER-2 were observed in 29% and 11% of tumors, respectively. P-Akt expression was found in 73% of tumors. Significant correlations between EGFR TGF-alpha or coexpression of TGF-alpha & EGFR and p-Akt expression were found (p=0.006, 0.008 and 0.010, respectively). No proteins examined had an impact on relapse-free survival.
CONCLUSION: The Akt pathway is frequently involved in NSCLC and overexpression of EGFR and autocrine expression of TGF-alpha may increase the potency of Akt activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015570

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

Review 1.  Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Authors:  Po Yee Yip
Journal:  Transl Lung Cancer Res       Date:  2015-04

2.  NADPH oxidase NOX1 controls autocrine growth of liver tumor cells through up-regulation of the epidermal growth factor receptor pathway.

Authors:  Patricia Sancho; Isabel Fabregat
Journal:  J Biol Chem       Date:  2010-06-04       Impact factor: 5.157

3.  Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.

Authors:  H Nakamura; N Kawasaki; M Taguchi; K Kabasawa
Journal:  Thorax       Date:  2005-11-11       Impact factor: 9.139

4.  Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system.

Authors:  Andrew V Kossenkov; Anil Vachani; Celia Chang; Calen Nichols; Shere Billouin; Wenhwai Horng; William N Rom; Steven M Albelda; Michael K Showe; Louise C Showe
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

5.  Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1.

Authors:  Gunamani Sithanandam; George T Smith; Janet R Fields; Laura W Fornwald; Lucy M Anderson
Journal:  Am J Respir Cell Mol Biol       Date:  2005-07-29       Impact factor: 6.914

6.  [6]-shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2.

Authors:  Myoung Ok Kim; Mee-Hyun Lee; Naomi Oi; Sung-Hyun Kim; Ki Beom Bae; Zunnan Huang; Dong Joon Kim; Kanamata Reddy; Sung-Young Lee; Si Jun Park; Jae Young Kim; Hua Xie; Joydeb Kumar Kundu; Zae Young Ryoo; Ann M Bode; Young-Joon Surh; Zigang Dong
Journal:  Carcinogenesis       Date:  2013-11-26       Impact factor: 4.944

Review 7.  Beyond DNA repair: DNA-PK function in cancer.

Authors:  Jonathan F Goodwin; Karen E Knudsen
Journal:  Cancer Discov       Date:  2014-08-28       Impact factor: 39.397

Review 8.  Epidermal growth factor receptor inhibitors in non-small cell lung cancer.

Authors:  Janet E Dancey
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Up-regulation of SRPK1 in non-small cell lung cancer promotes the growth and migration of cancer cells.

Authors:  Hongcheng Liu; Xuefei Hu; Yuming Zhu; Gening Jiang; Sheng Chen
Journal:  Tumour Biol       Date:  2015-12-14

10.  Opposing functions of Akt isoforms in lung tumor initiation and progression.

Authors:  Nicolle M Linnerth-Petrik; Lisa A Santry; James J Petrik; Sarah K Wootton
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.